| Literature DB >> 28184026 |
Yuanyuan Zhu1, Chao Yang2, Mingjiao Weng2, Yan Zhang3, Chunhui Yang4, Yinji Jin2, Weiwei Yang2, Yan He2, Yiqi Wu2, Yuhua Zhang2, Guangyu Wang1, Riju James RajkumarEzakiel Redpath2, Lei Zhang2, Xiaoming Jin2, Ying Liu3, Yuchun Sun5, Ning Ning6, Yu Qiao7, Fengmin Zhang8, Zhiwei Li1, Tianzhen Wang2, Yanqiao Zhang1, Xiaobo Li2,9.
Abstract
Numerous evidences indicate that aspirin usage causes a significant reduction in colorectal cancer. However, the molecular mechanisms about aspirin preventing colon cancer are largely unknown. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) is a most frequently used method to identify the target molecules regulated by certain compound. However, this method needs stable internal reference genes to analyze the expression change of the targets. In this study, the transcriptional stabilities of several traditional reference genes were evaluated in colon cancer cells treated with aspirin, and also, the suitable internal reference genes were screened by using a microarray and were further identified by using the geNorm and NormFinder softwares, and then were validated in more cell lines and xenografts. We have showed that three traditional internal reference genes, β-actin, GAPDH and α-tubulin, are not suitable for studying gene transcription in colon cancer cells treated with aspirin, and we have identified and validated TMEM208 and PQLC2 as the ideal internal reference genes for detecting the molecular targets of aspirin in colon cancer in vitro and in vivo. This study reveals stable internal reference genes for studying the target genes of aspirin in colon cancer, which will contribute to identify the molecular mechanism behind aspirin preventing colon cancer.Entities:
Keywords: aspirin; colorectal cancer; reference gene
Mesh:
Substances:
Year: 2017 PMID: 28184026 PMCID: PMC5410260 DOI: 10.18632/oncotarget.15191
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Screening the doses of aspirin to identify the reference genes in colon cancer cells treated with aspirin
(A) Screening the dose of aspirin in HCT116 cells by detecting its inhibitory effect on cell proliferation. (B) Screening the dose of aspirin in DLD1 cells by detecting its inhibitory effect on cell proliferation. (C) Screening the dose of aspirin in SW620 cells by detecting its inhibitory effect on cell proliferation. (D) Detection of the expression of GAPDH in three colon cancer cell lines treated with aspirin. E. Detection of the expression of β-actin in three colon cancer cell lines treated with aspirin.
Figure 2Screening candidate reference genes for normalizing mRNA expression in aspirin treated colon cancer cells
(A) Thirteen stably expressed genes were screened as the candidates of the internal reference genes by using microarray. (B) There are totally 59 transcripts significantly changed in three cell lines after aspirin treatment. (C) The commonly down-regulated mRNA in three cell lines after aspirin treatment. (D) The commonly up-regulated mRNA in three cell lines after aspirin treatment.
The list of candidate internal reference genes
| Number | Gene Symbol | Description | Chromosome |
|---|---|---|---|
| 1 | TMEM208 | transmembrane protein 208 | Chr16 |
| 2 | GUSBP5 | glucuronidase, beta pseudogene 5 | Chr4 |
| 3 | KRTAP1-3 | keratin associated protein 1-3 | Chr17 |
| 4 | RPS25 | ribosomal protein S25 | Chr11 |
| 5 | SLC18A3 | solute carrier family 18 (vesicular acetylcholine), member 3 | Chr10 |
| 6 | MTDH | metadherin | Chr8 |
| 7 | RPL36 | ribosomal protein L36 | Chr19 |
| 8 | PQLC2 | PQ loop repeat containing 2 | Chr1 |
| 9 | FAM208B | family with sequence similarity 208, member B | Chr10 |
| 10 | NDST2 | N-deacetylase/N-sulfotransferase (heparanglucosaminyl) 2 | Chr10 |
| 11 | IL17RC | interleukin 17 receptor C | Chr3 |
| 12 | RPL8 | ribosomal protein L8 | Chr8 |
| 13 | RPL23A | ribosomal protein L23a | Chr17 |
Figure 3Identifying reference genes for normalizing mRNA expression in aspirin treated DLD1 cells
(A) Identifying reference genes by using geNorm software. (B) Identifying reference genes by using NormFinder software. (C) Optimizing the number of reference genes in aspirin treated DLD1 cells.
Figure 4Identifying reference genes for normalizing mRNA expression in aspirin treated SW620 cells
(A) Identifying reference genes by using geNorm software. (B) Identifying reference genes by using NormFinder software. (C) Optimizing the number of reference genes in aspirin treated SW620 cells.
Figure 5Identifying reference genes for normalizing mRNA expression in aspirin treated HCT116 cells
(A) Identifying reference genes by using geNorm software. (B) Identifying reference genes by using NormFinder software. (C) Optimizing the number of reference genes in aspirin treated HCT116 cells.
Summary about the stable reference genes in three colon cancer cells
| Cell lines | Stably expressed genes identified by geNorm | Stably expressed genes identified by NormFinder | Commonly identified reference genes |
|---|---|---|---|
| DLD1 | RPL36, FAM208B, IL17RC, | MTDH, PQLC2, KRTAP1, TMEM208 | MTDH, TMEM208, PQLC2, KRTAP1, |
| SW620 | TMEM208, PQLC2 | ||
| HCT116 | PQLC2, RPS25, GUSBP5, TMEM208, RPL8, FAM208B | RPL36, PQLC2, FAM208, GUSBP5, IL17RC, TMEM208 | PQLC2, TMEM208, FAM208, GUSBP5 |
Figure 6Validation of TMEM208 and PQLC2 as ideal reference genes in colon cancer cells
(A) Validation of TMEM208 and PQLC2 as ideal reference genes in SW480 and SW1116 cells. (B) Changing the concentrations of aspirin does not alter the expression of TMEM208 and PQLC2. (C) aspirin treatment does not affect the mRNA decay of TMEM208 and PQLC2. (D) Validation of the down-regulated genes in three colon cancer cells treated with aspirin using PQLC2 as internal reference gene. (E) Validation of the up-regulated genes in three colon cancer cells treated with aspirin using PQLC2 as internal reference gene.
Figure 7Validation of TMEM208 and PQLC2 as the ideal internal reference gene in xenograft of colon cancer treated with aspirin
(A) The illustration of nude mice bearing colon cancer subcutaneously. (B) The illustration of tumors with and without aspirin treatment. (C) aspirin treatment significantly decreased the weight of tumor xenografts in vivo (p < 0.05). (D) The expression of TMEM208 and PQLC2 is not altered in the xenografts of colon cancer after aspirin treatment. (E) The relative expression of several selected genes (three traditional reference genes and two novel identified target genes of aspirin) in the xenografts treated with aspirin (100 mg) normalized with PQLC2.
Primers used in this study
| Gene Name | Primers(5′-3′) | Product(bp) |
|---|---|---|
| RPS25 | F:CGCCTAAGGACGACAAGA | 112 |
| R:TTGCCTTTGGACCACTTC | ||
| GUSBP5 | F:GGGATGCTGTACCCAAGA | 126 |
| R:CAGACGCCGATACCACTA | ||
| SLC18A3 | F:GAGCCACCGCAAGGTCTGT | 107 |
| R:TCCTCGCACGCATCAAAA | ||
| MTDH | F:AAACGTGATAAGGTGCTG | 105 |
| R:AAATGATGCGGTTGTAAG | ||
| RPL36 | F:TCGTGCGGGACATGATTC | 150 |
| R:CCCCACCCTTTTCTTGATA | ||
| KRTAP1-3 | F:GCGGATTTCCTAGCTTCTCA | 150 |
| R:CCACCTGATACGGGTGCT | ||
| FAM208B | F:TATCCTTCCGTGATCCTA | 137 |
| R:ATTCTGGTCTTCTTGGGT | ||
| TMEM208 | F:GTCTGGTCCTTCTGGCTTCT | 122 |
| R:TGCCGTTTCTCATTGTGC | ||
| RPL23A | F:CCAACAAGCACCAGATTA | 117 |
| R:CAGGAGCCAGTCGAACAT | ||
| RPL8 | F:GCACGGCTACATCAAGGG | 130 |
| R:CTCGGCGGCAATGAACAG | ||
| IL17RC | F:GGAGCCGTCGTGAACTGA | 143 |
| R:CCCATCCTGTAGCCACTCG | ||
| NDST2 | F:TTGACCGCTACATCTTGG | 108 |
| R:TGAGTTTGTTCTGGGTGG | ||
| PQLC2 | F:GCCTCAGATCCGCACCAA | 104 |
| R:GCACGCTCAGCCCATACA | ||
| GAPDH | F:GACCTGACCTGCCGTCTA | 148 |
| R:AGGAGTGGGTGTCGCTGT | ||
| ACTB | F:GGAAATCGTGCGTGACATT | 113 |
| R:CAGGCAGCTCGTAGCTCTT | ||
| TUBA1A | F:CTTGGAACCCACAGTCATT | 112 |
| R:CCCTCGGGCATAGTTATT |